Stryker Corporation (SYK) earnings on April 30, 2026
More Stryker Corporation earnings
Prior outlook: Pessimistic Outcome: Accurate
The stock barely moved at the start of market review, then dropped sharply. It ended the day down about 6.5%.
SYK price around the earnings
294.73
Change: -6.5%
2026-05-01, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Accurate
- Thesis published
The scenario suggests caution; risks appear elevated.
Despite positive analyst price targets, the stock is showing weakness and negative sentiment due to recent news and underperformance compared to the market.
Context analyzed before publication
- Summary
- The scenario suggests caution; risks appear elevated.
- Reasoning
- Despite positive analyst price targets, the stock is showing weakness and pessimistic sentiment due to recent news and underperformance compared to the market.
- Playbook
- Given the recent weakness and negative news, the scenario suggests a need for clearer positive contexts or a more attractive price level.
- Trend
- Outlook deteriorating, weakness persists.
Analysts
Drivers
-
Analysts
Positive
Analysts generally recommend buying the stock and have set price targets that point to a considerably optimistic scenario. However, some analysts have maintained neutral ratings or lowered their targets.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.76
- Analysts covering the stock
- 27
- Average price target
- 419.11
- Lowest price target
- 316
- Highest price target
- 469
- Upside to price target
- 28.1%
- Quarterly earnings growth
- 55.5%
- Revenue growth
- 11.4%
- Forward EPS
- 16.74
- Trailing EPS
- 8.12
- Analyst moves in the last 60 days
- 8
- Strong buy: 8
- Buy: 14
- Hold: 7
- Sell: 0
- Strong sell: 0
- Strong buy
- 8
- Buy
- 14
- Hold
- 7
- Sell
- 0
- Strong sell
- 0
- April 15, 2026 · Truist Securities: Maintains rating (Hold → Hold)
- April 14, 2026 · BTIG: Reiterates rating (Buy → Buy)
- April 13, 2026 · Leerink Partners: Initiates coverage (Outperform)
- April 9, 2026 · Goldman Sachs: Maintains rating (Neutral → Neutral)
- April 7, 2026 · Citigroup: Maintains rating (Buy → Buy)
- April 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
- March 17, 2026 · UBS: Maintains rating (Neutral → Neutral)
- February 24, 2026 · UBS: Maintains rating (Neutral → Neutral)
News and sentiment
Drivers
-
News & sentiment
Negative
Negative news, including a product safety concern and a reduced price target from one analyst, is influencing sentiment. While social media shows optimistic sentiment, it is not strongly supported by market review activity.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (8)
- Stryker Updates Use Instructions For Patient-Fitted TMJ Implants; As Of Dec 4, Stryker Reported One Serious Injury & No Deaths Associated With Patient-Fitted TMJ Implants Issue — Benzinga
- Truist Securities Maintains Hold on Stryker, Lowers Price Target to $380 — Benzinga
- BTIG Reiterates Buy on Stryker, Maintains $397 Price Target — Benzinga
- Stryker To Acquire Amplitude Vascular Systems, The Developer Of A Next-Generation Intravascular Lithotripsy Platform; Terms Not Disclosed — Benzinga
- Stryker Says Cybersecurity Incident Had Material Impact On Q1 2026 Financial Results; Co. Believes Cybersecurity Incident Not Expected To Materially Impact 2026 FY Guidance — Benzinga
- Goldman Sachs Maintains Neutral on Stryker, Lowers Price Target to $357 — Benzinga
- Evercore ISI Group Maintains Outperform on Stryker, Lowers Price Target to $365 — Benzinga
- Stryker Says Has Not Yet Determined Whether Cybersecurity Incident Is Likely To Have Material Impact On Co; No Malicious Activity Identified Toward Customers, Suppliers, Vendors, Or Partners; Investigation Ongoing — Benzinga
Technicals
Drivers
-
Technical
Negative
The stock's recent performance has lagged the broader market, indicating weakness. It is currently market review near a support level, which could mean a more pessimistic scenario is possible.
Evidence
- Average true range (ATR)
- 2.4%
- Distance to 52-week high
- -19.2%
- 14-day change (14d)
- -0.7%
- 30-day change
- -8.8%
- 30-day relative strength
- -12.5%
- Benchmark change
- +3.8%
- Nearest support
- 319.77
- Nearest resistance
- 364.28
- Volume accumulation ratio
- 0.97
Trends
Evidence
- Average earnings surprise
- -8.8%
- January 29, 2026: actual EPS 4.47 vs estimate 4.4 (surprise +1.7%)
- October 30, 2025: actual EPS 2.22 vs estimate 2.56 (surprise -13.2%)
- July 31, 2025: actual EPS 3.13 vs estimate 3.07 (surprise +1.9%)
- May 1, 2025: actual EPS 1.69 vs estimate 2.28 (surprise -25.8%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 2.5%
- 75th percentile move
- 3.9%
- 90th percentile move
- 4.8%
- Up / down moves
- 9 / 10
- Average up move
- +3.4%
- Average down move
- -2.4%
Monitoring and close
What Stryker Corporation reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- -6.5%
- Max favorable move (MFE)
- 6.5%
- Max adverse move (MAE)
- 0%